Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.77 |
| ▸ | RAB9A | P51151 | 2/20 | 0.77 |
| ▸ | LMNA | P02545 | 1/20 | 0.67 |
| ▸ | ACACB | O00763 | 1/20 | 0.59 |
| ▸ | OPRM1 | P35372 | 7/20 | 0.58 |
| ▸ | OPRK1 | P41145 | 5/20 | 0.58 |
| ▸ | OPRD1 | P41143 | 4/20 | 0.58 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.56 |
| ▸ | EPHX2 | P34913 | 2/20 | 0.56 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.56 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.51 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12204095 | 1.00 | NPC1 (0.77) | NPC1RAB9ALMNAACACBOPRM1 | |
| SCHEMBL14654946 | 0.88 | NPC1 (1.00) | NPC1RAB9ALMNAOPRM1OPRK1 | |
| SCHEMBL10429991 | 0.83 | LMNA (0.67) | LMNAGAAKMT2A | |
| SCHEMBL11581315 | 0.83 | NPC1 (0.83) | NPC1RAB9ALMNAOPRM1OPRK1 | |
| SCHEMBL7445998 | 0.81 | CAPN1 (0.55) | NPC1RAB9A | |
| SCHEMBL24609344 | 0.80 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1SIGMAR1 | |
| SCHEMBL2543698 | 0.80 | NPC1 (0.79) | NPC1RAB9ALMNATAAR1SIGMAR1 | |
| SCHEMBL21992681 | 0.80 | NPC1 (0.67) | NPC1RAB9ALMNAOPRM1OPRK1 | |
| SCHEMBL11580858 | 0.80 | NPC1 (0.77) | NPC1RAB9ALMNATAAR1EPHX2 | |
| SCHEMBL7445995 | 0.80 | NPC1 (0.49) | NPC1RAB9ALMNAACACBEPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | CORNELL UNIVERSITY | 2023-09-14 | — | — | US | disclosed |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | CORNELL UNIVERSITY | 2023-09-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230285570-A1 | THERAPEUTICALLY USEFUL CURE-PRO MOLECULES FOR E3 LIGASE MEDIATED DEGRADATION OF PROTEINS, AND METHODS OF MAKING AND USING THEM | XIAP, CUL4A, CUL1 | NPC1 3588/4885RAB9A 3063/4885LMNA 1674/4885 |
| US-20230277553-A1 | THERAPEUTIC COMPOSITION OF CURE-PRO COMPOUNDS FOR TARGETED DEGRADATION OF BET DOMAIN PROTEINS, AND METHODS OF MAKING AND USAGE | BET1, BRD4, PHKB | NPC1 3741/4885RAB9A 3432/4885LMNA 1366/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.